CA2683015A1 - Compositions de cicatrisation contenant des biomateriaux keratiniques - Google Patents

Compositions de cicatrisation contenant des biomateriaux keratiniques Download PDF

Info

Publication number: CA2683015A1
Authority: CA; Canada
Prior art keywords: keratin derivative; kerateine; keratose; keratin; consists essentially
Prior art date: 2007-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA002683015A

Other languages

English (en)

Other versions

CA2683015C (fr

Inventor

Mark E. Van Dyke

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wake Forest University Health Sciences

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-17

Filing date

2008-04-17

Publication date

2008-10-30

2008-04-17 Application filed by Individual filed Critical Individual

2008-10-30 Publication of CA2683015A1 publication Critical patent/CA2683015A1/fr

2016-11-08 Application granted granted Critical

2016-11-08 Publication of CA2683015C publication Critical patent/CA2683015C/fr

Status Active legal-status Critical Current

2028-04-17 Anticipated expiration legal-status Critical

Links

108010076876 Keratins Proteins 0.000 title claims abstract description 309
102000011782 Keratins Human genes 0.000 title claims abstract description 309
239000000203 mixture Substances 0.000 title claims description 76
239000012620 biological material Substances 0.000 title description 22
230000029663 wound healing Effects 0.000 title description 15
208000027418 Wounds and injury Diseases 0.000 claims abstract description 159
206010052428 Wound Diseases 0.000 claims abstract description 138
238000000034 method Methods 0.000 claims abstract description 120
238000011282 treatment Methods 0.000 claims abstract description 31
238000002360 preparation method Methods 0.000 claims abstract description 20
239000000758 substrate Substances 0.000 claims abstract description 14
206010020649 Hyperkeratosis Diseases 0.000 claims description 146
230000002378 acidificating effect Effects 0.000 claims description 85
208000014674 injury Diseases 0.000 claims description 35
230000006378 damage Effects 0.000 claims description 30
239000000843 powder Substances 0.000 claims description 19
230000008569 process Effects 0.000 claims description 19
239000007787 solid Substances 0.000 claims description 17
238000006243 chemical reaction Methods 0.000 claims description 16
238000004255 ion exchange chromatography Methods 0.000 claims description 15
239000004599 antimicrobial Substances 0.000 claims description 12
208000034693 Laceration Diseases 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 9
239000006071 cream Substances 0.000 claims description 9
239000002674 ointment Substances 0.000 claims description 9
238000005299 abrasion Methods 0.000 claims description 7
206010011985 Decubitus ulcer Diseases 0.000 claims description 6
208000023329 Gun shot wound Diseases 0.000 claims description 6
208000004210 Pressure Ulcer Diseases 0.000 claims description 6
239000008365 aqueous carrier Substances 0.000 claims description 6
230000003115 biocidal effect Effects 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
230000035515 penetration Effects 0.000 claims description 6
108010001478 Bacitracin Proteins 0.000 claims description 5
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 claims description 5
108010093965 Polymyxin B Proteins 0.000 claims description 5
229940035676 analgesics Drugs 0.000 claims description 5
239000000730 antalgic agent Substances 0.000 claims description 5
229960003071 bacitracin Drugs 0.000 claims description 5
229930184125 bacitracin Natural products 0.000 claims description 5
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 5
229960003548 polymyxin b sulfate Drugs 0.000 claims description 5
229930193140 Neomycin Natural products 0.000 claims description 4
239000004744 fabric Substances 0.000 claims description 4
229960004927 neomycin Drugs 0.000 claims description 4
238000012856 packing Methods 0.000 claims description 4
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 3
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
229930182566 Gentamicin Natural products 0.000 claims description 3
UILOTUUZKGTYFQ-UHFFFAOYSA-N Mafenide acetate Chemical compound CC(O)=O.NCC1=CC=C(S(N)(=O)=O)C=C1 UILOTUUZKGTYFQ-UHFFFAOYSA-N 0.000 claims description 3
229920000153 Povidone-iodine Polymers 0.000 claims description 3
229960002518 gentamicin Drugs 0.000 claims description 3
229960002721 mafenide acetate Drugs 0.000 claims description 3
229940049337 neosporin Drugs 0.000 claims description 3
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 3
229960001907 nitrofurazone Drugs 0.000 claims description 3
229960000988 nystatin Drugs 0.000 claims description 3
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 3
108010046630 polymyxin B drug combination bacitracin Proteins 0.000 claims description 3
229940103255 polysporin Drugs 0.000 claims description 3
229960001621 povidone-iodine Drugs 0.000 claims description 3
229960003600 silver sulfadiazine Drugs 0.000 claims description 3
UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims description 3
239000003357 wound healing promoting agent Substances 0.000 claims description 3
239000011888 foil Substances 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000000202 analgesic effect Effects 0.000 claims 2
239000000243 solution Substances 0.000 description 99
241001465754 Metazoa Species 0.000 description 66
GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 49
210000004209 hair Anatomy 0.000 description 44
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
102000004169 proteins and genes Human genes 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 34
235000018102 proteins Nutrition 0.000 description 33
210000001519 tissue Anatomy 0.000 description 33
210000004369 blood Anatomy 0.000 description 31
239000008280 blood Substances 0.000 description 31
239000000499 gel Substances 0.000 description 30
208000032843 Hemorrhage Diseases 0.000 description 28
239000002874 hemostatic agent Substances 0.000 description 26
230000000740 bleeding effect Effects 0.000 description 25
229940030225 antihemorrhagics Drugs 0.000 description 24
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 23
230000002439 hemostatic effect Effects 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
238000000605 extraction Methods 0.000 description 21
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 20
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 20
239000003102 growth factor Substances 0.000 description 19
210000003491 skin Anatomy 0.000 description 19
239000000835 fiber Substances 0.000 description 18
238000006722 reduction reaction Methods 0.000 description 17
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 16
210000004185 liver Anatomy 0.000 description 16
239000000463 material Substances 0.000 description 15
230000009467 reduction Effects 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000007983 Tris buffer Substances 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
239000002253 acid Substances 0.000 description 13
238000007254 oxidation reaction Methods 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
239000000284 extract Substances 0.000 description 12
230000012010 growth Effects 0.000 description 12
239000013642 negative control Substances 0.000 description 12
230000003647 oxidation Effects 0.000 description 12
230000000694 effects Effects 0.000 description 11
238000001914 filtration Methods 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
108010025020 Nerve Growth Factor Proteins 0.000 description 10
239000004202 carbamide Substances 0.000 description 10
238000000502 dialysis Methods 0.000 description 10
239000007788 liquid Substances 0.000 description 10
239000000523 sample Substances 0.000 description 10
230000035939 shock Effects 0.000 description 10
208000001126 Keratosis Diseases 0.000 description 9
-1 coatings Substances 0.000 description 9
238000004108 freeze drying Methods 0.000 description 9
230000008595 infiltration Effects 0.000 description 9
238000001764 infiltration Methods 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
206010067125 Liver injury Diseases 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
210000003963 intermediate filament Anatomy 0.000 description 8
230000017074 necrotic cell death Effects 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 8
238000001556 precipitation Methods 0.000 description 8
239000011347 resin Substances 0.000 description 8
229920005989 resin Polymers 0.000 description 8
230000004083 survival effect Effects 0.000 description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
208000007536 Thrombosis Diseases 0.000 description 7
230000001464 adherent effect Effects 0.000 description 7
239000000908 ammonium hydroxide Substances 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
230000034994 death Effects 0.000 description 7
231100000517 death Toxicity 0.000 description 7
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
210000002950 fibroblast Anatomy 0.000 description 7
210000003780 hair follicle Anatomy 0.000 description 7
231100000753 hepatic injury Toxicity 0.000 description 7
238000001356 surgical procedure Methods 0.000 description 7
230000008733 trauma Effects 0.000 description 7
102000015336 Nerve Growth Factor Human genes 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
230000002776 aggregation Effects 0.000 description 6
238000004220 aggregation Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000035876 healing Effects 0.000 description 6
229910052500 inorganic mineral Inorganic materials 0.000 description 6
210000002510 keratinocyte Anatomy 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
150000002739 metals Chemical class 0.000 description 6
239000011707 mineral Substances 0.000 description 6
229940053128 nerve growth factor Drugs 0.000 description 6
230000001590 oxidative effect Effects 0.000 description 6
238000011069 regeneration method Methods 0.000 description 6
210000002268 wool Anatomy 0.000 description 6
208000009043 Chemical Burns Diseases 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
102100037362 Fibronectin Human genes 0.000 description 5
108010067306 Fibronectins Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
125000000129 anionic group Chemical group 0.000 description 5
230000004872 arterial blood pressure Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
238000007906 compression Methods 0.000 description 5
230000006835 compression Effects 0.000 description 5
229960001484 edetic acid Drugs 0.000 description 5
210000002615 epidermis Anatomy 0.000 description 5
210000003743 erythrocyte Anatomy 0.000 description 5
210000003284 horn Anatomy 0.000 description 5
239000000017 hydrogel Substances 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000008929 regeneration Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
208000018380 Chemical injury Diseases 0.000 description 4
206010053567 Coagulopathies Diseases 0.000 description 4
229920002271 DEAE-Sepharose Polymers 0.000 description 4
108010073385 Fibrin Proteins 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
102000007072 Nerve Growth Factors Human genes 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
229910021536 Zeolite Inorganic materials 0.000 description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000003139 buffering effect Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
239000002738 chelating agent Substances 0.000 description 4
239000003638 chemical reducing agent Substances 0.000 description 4
230000035602 clotting Effects 0.000 description 4
239000000470 constituent Substances 0.000 description 4
239000008367 deionised water Substances 0.000 description 4
229910021641 deionized water Inorganic materials 0.000 description 4
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
108010008217 nidogen Proteins 0.000 description 4
239000003921 oil Substances 0.000 description 4
229910052760 oxygen Inorganic materials 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000011160 research Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000002792 vascular Effects 0.000 description 4
239000010457 zeolite Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
206010019049 Hair texture abnormal Diseases 0.000 description 3
102000011733 Hair-Specific Keratins Human genes 0.000 description 3
108010037031 Hair-Specific Keratins Proteins 0.000 description 3
102000007547 Laminin Human genes 0.000 description 3
108010085895 Laminin Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108090000742 Neurotrophin 3 Proteins 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000010171 animal model Methods 0.000 description 3
210000000702 aorta abdominal Anatomy 0.000 description 3
239000003114 blood coagulation factor Substances 0.000 description 3
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000021164 cell adhesion Effects 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000008602 contraction Effects 0.000 description 3
230000007423 decrease Effects 0.000 description 3
210000004207 dermis Anatomy 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000008151 electrolyte solution Substances 0.000 description 3
238000010828 elution Methods 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
210000000003 hoof Anatomy 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
230000003993 interaction Effects 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000001694 spray drying Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000008961 swelling Effects 0.000 description 3
230000000451 tissue damage Effects 0.000 description 3
230000009772 tissue formation Effects 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
229910052723 transition metal Inorganic materials 0.000 description 3
150000003624 transition metals Chemical class 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical compound NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 2
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
102000003951 Erythropoietin Human genes 0.000 description 2
108090000394 Erythropoietin Proteins 0.000 description 2
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102100037852 Insulin-like growth factor I Human genes 0.000 description 2
102000015728 Mucins Human genes 0.000 description 2
108010063954 Mucins Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010056852 Myostatin Proteins 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
238000011887 Necropsy Methods 0.000 description 2
102100029268 Neurotrophin-3 Human genes 0.000 description 2
102000003683 Neurotrophin-4 Human genes 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
102100037369 Nidogen-1 Human genes 0.000 description 2
108010067787 Proteoglycans Proteins 0.000 description 2
102000016611 Proteoglycans Human genes 0.000 description 2
239000012614 Q-Sepharose Substances 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
241000282887 Suidae Species 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
206010053615 Thermal burn Diseases 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
108010031318 Vitronectin Proteins 0.000 description 2
102100035140 Vitronectin Human genes 0.000 description 2
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
238000001804 debridement Methods 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
229960005215 dichloroacetic acid Drugs 0.000 description 2
238000004821 distillation Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
230000002500 effect on skin Effects 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
229940105423 erythropoietin Drugs 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000006260 foam Substances 0.000 description 2
230000000855 fungicidal effect Effects 0.000 description 2
239000000417 fungicide Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000010150 least significant difference test Methods 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000005228 liver tissue Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
230000001338 necrotic effect Effects 0.000 description 2
229940032018 neurotrophin 3 Drugs 0.000 description 2
229940097998 neurotrophin 4 Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
230000036407 pain Effects 0.000 description 2
238000002161 passivation Methods 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000009877 rendering Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000009938 salting Methods 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000036575 thermal burns Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000004246 zinc acetate Substances 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 1
244000045410 Aegopodium podagraria Species 0.000 description 1
235000007237 Aegopodium podagraria Nutrition 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
235000014429 Angelica sylvestris Nutrition 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
206010006802 Burns second degree Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000819038 Chichester Species 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
206010056340 Diabetic ulcer Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010051814 Eschar Diseases 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
108010071289 Factor XIII Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
102000000795 Galectin 1 Human genes 0.000 description 1
108010001498 Galectin 1 Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
QSDSSSQWVNLFIG-UHFFFAOYSA-N Neosporin Natural products CC(O)CC1=C(OC)C(=O)C2=CC(O)=C3OCOC4=C(O)C=C5C6=C4C3=C2C1=C6C(CC(C)O)=C(OC)C5=O QSDSSSQWVNLFIG-UHFFFAOYSA-N 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
102100032889 Sortilin Human genes 0.000 description 1
206010041662 Splinter Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000031737 Tissue Adhesions Diseases 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
238000007605 air drying Methods 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
210000003323 beak Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
238000010504 bond cleavage reaction Methods 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000003486 chemical etching Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
229940045110 chitosan Drugs 0.000 description 1
229960003333 chlorhexidine gluconate Drugs 0.000 description 1
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000001351 cycling effect Effects 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000009699 differential effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000011496 digital image analysis Methods 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
108010046161 drug combination polymyxin B neomycin sulfate bacitracin zinc Proteins 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000005584 early death Effects 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000005175 epidermal keratinocyte Anatomy 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
231100000333 eschar Toxicity 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229940012444 factor xiii Drugs 0.000 description 1
239000011552 falling film Substances 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
210000003746 feather Anatomy 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000010408 film Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
210000005161 hepatic lobe Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
229940056582 human hair preparation Drugs 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
239000013541 low molecular weight contaminant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000002398 materia medica Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
108700005457 microfibrillar Proteins 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
238000009448 modified atmosphere packaging Methods 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
238000012806 monitoring device Methods 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000007514 neuronal growth Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
238000005691 oxidative coupling reaction Methods 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000000554 physical therapy Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
238000013310 pig model Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009979 protective mechanism Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000011946 reduction process Methods 0.000 description 1
230000025078 regulation of biosynthetic process Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000012465 retentate Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
210000004918 root sheath Anatomy 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
229940046307 sodium thioglycolate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
239000003860 topical agent Substances 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
229910021642 ultra pure water Inorganic materials 0.000 description 1
239000012498 ultrapure water Substances 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229940054870 urso Drugs 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Materials Engineering (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Hematology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Oral & Maxillofacial Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2683015A 2007-04-17 2008-04-17 Compositions de cicatrisation contenant des biomateriaux keratiniques Active CA2683015C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US91226507P	2007-04-17	2007-04-17
US60/912,265		2007-04-17
PCT/US2008/004984 WO2008130607A2 (fr)	2007-04-17	2008-04-17	Compositions de cicatrisation contenant des biomatériaux kératiniques

Publications (2)

Publication Number	Publication Date
CA2683015A1 true CA2683015A1 (fr)	2008-10-30
CA2683015C CA2683015C (fr)	2016-11-08

Family

ID=39876125

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2683015A Active CA2683015C (fr)	2007-04-17	2008-04-17	Compositions de cicatrisation contenant des biomateriaux keratiniques

Country Status (7)

Country	Link
EP (1)	EP2146738A2 (fr)
JP (1)	JP5868592B2 (fr)
CN (1)	CN101730540A (fr)
AU (1)	AU2008241396B2 (fr)
CA (1)	CA2683015C (fr)
IL (1)	IL201425A0 (fr)
WO (1)	WO2008130607A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2542564B1 (fr) *	2010-03-05	2018-05-09	Wake Forest University Health Sciences	Système d'administration contrôlée
EP2640408B1 (fr)	2010-11-17	2016-05-25	Wake Forest University Health Sciences	Compositions kératiniques pour le traitement d'une déficience ou lésion osseuse
WO2013025941A1 (fr)	2011-08-17	2013-02-21	Keranetics Llc	Compositions gélifiantes à faible concentration en protéines
WO2013025928A2 (fr)	2011-08-17	2013-02-21	Keranetics Llc	Procédés d'extraction de protéines de la kératine
US9827245B2 (en)	2013-03-15	2017-11-28	KeraNetics, LLC	Keratin compositions comprising halofuginone
US11273118B2 (en)	2014-06-04	2022-03-15	Zim Biosciences, Inc.	Compositions and methods for improving skin quality
JP6637241B2 (ja) *	2015-03-02	2020-01-29	アドバンス株式会社	可溶性ケラテインの製造法
CN106473945A (zh) *	2016-07-21	2017-03-08	北京东方艾美生物技术股份有限公司	一种角蛋白面膜的制备方法
JPWO2018220739A1 (ja) *	2017-05-31	2020-08-13	株式会社リトル・サイエンティスト	高収率で得られるケラチン誘導体とその使用方法
CN112724227B (zh) *	2019-10-28	2023-09-26	中国医学科学院药物研究所	一种角蛋白bd-1、制法和其药物组合物与用途
CN112794894B (zh) *	2019-10-28	2023-09-26	中国医学科学院药物研究所	一种角蛋白bd-17、制法和其药物组合物与用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4570629A (en) *	1982-03-17	1986-02-18	University Of Illinois Foundation	Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
CA1213520A (fr) *	1982-03-17	1986-11-04	Abe Widra	Copolyelectrolytes biopolymeres hydrophiles, et pansements biodegradables qui les renferment
FR2661414B1 (fr) *	1990-04-25	1995-03-24	Michel Jean Pierre	Produit a base de keratines modifiees, son procede de preparation et les applications notamment en medecine humaine ou veterinaire.
US6270791B1 (en) *	1999-06-11	2001-08-07	Keraplast Technologies, Ltd.	Soluble keratin peptide
US6371984B1 (en) *	1999-09-13	2002-04-16	Keraplast Technologies, Ltd.	Implantable prosthetic or tissue expanding device
US6544548B1 (en) *	1999-09-13	2003-04-08	Keraplast Technologies, Ltd.	Keratin-based powders and hydrogel for pharmaceutical applications
US6270793B1 (en) *	1999-09-13	2001-08-07	Keraplast Technologies, Ltd.	Absorbent keratin wound dressing
CA2474723A1 (fr) *	2002-01-28	2003-08-07	Keraplast Technologies, Ltd.	Peptides bioactifs de keratine
DE60331638D1 (de) *	2002-04-10	2010-04-22	Keraplast Tech Ltd	Keratin-netzwerke enthaltende wundverbände für gewebedefekte
EP1983927B1 (fr) *	2006-02-17	2014-11-05	Wake Forest University Health Sciences	Revêtements et implants biomédicaux constitués de biomatériaux de kératine

2008
- 2008-04-17 CN CN200880020599A patent/CN101730540A/zh active Pending
- 2008-04-17 AU AU2008241396A patent/AU2008241396B2/en not_active Ceased
- 2008-04-17 WO PCT/US2008/004984 patent/WO2008130607A2/fr not_active Ceased
- 2008-04-17 EP EP08743024A patent/EP2146738A2/fr not_active Withdrawn
- 2008-04-17 CA CA2683015A patent/CA2683015C/fr active Active
- 2008-04-17 JP JP2010504088A patent/JP5868592B2/ja active Active
2009
- 2009-10-11 IL IL201425A patent/IL201425A0/en unknown

Also Published As

Publication number	Publication date
WO2008130607A3 (fr)	2009-02-26
JP2010524943A (ja)	2010-07-22
WO2008130607A2 (fr)	2008-10-30
IL201425A0 (en)	2010-05-31
JP5868592B2 (ja)	2016-02-24
CN101730540A (zh)	2010-06-09
AU2008241396A1 (en)	2008-10-30
AU2008241396B2 (en)	2014-06-19
EP2146738A2 (fr)	2010-01-27
CA2683015C (fr)	2016-11-08

Publication	Publication Date	Title
US8258093B2 (en)	2012-09-04	Wound healing compositions containing keratin biomaterials
EP1991256B1 (fr)	2016-11-23	Compositions contenant des biomatériaux à base de kératine, destinées à induire la coagulation et la guérison
CA2683015C (fr)	2016-11-08	Compositions de cicatrisation contenant des biomateriaux keratiniques
Vasconcelos et al.	2013	The use of keratin in biomedical applications
EP0322249B1 (fr)	1993-05-26	Méthodes de préparation et compositions pharmaceutiques contenant des dérivés du collagène
EP0804257B1 (fr)	2003-07-09	Materiau du type feuille autonome compose de fibrine reticulee, destine a prevenir les adherences postoperatoires
WO1996040033A1 (fr)	1996-12-19	Timbre hemostatique non biologique
JP2002511489A (ja)	2002-04-16	液体媒体中の天然コラーゲンを滅菌する方法、得られた滅菌天然コラーゲン、それを含む組成物及びその使用
ES2216323T3 (es)	2004-10-16	Medicina para promover la cicatrizacion y que contiene trombocitos.
WO2013025940A1 (fr)	2013-02-21	Angiogenèse induite par l'alpha-kératose
US20210369598A1 (en)	2021-12-02	Compositions and methods relating to amnion
CN113194965B (zh)	2024-12-13	用于治疗伤口的药物组合物
Samsarga et al.	2020	Potential combinations of Platelet Rich Plasma (PRP) and chitosan in burn wound management: a review
RU2789304C1 (ru)	2023-02-01	Биоразлагаемая ранозаживляющая пленка
JPH0720873B2 (ja)	1995-03-08	創傷治癒剤
Ghafar et al.	0	In vivo application of Oreochromis niloticus scales collagen as alternative wound healing therapy
Zidan et al.	0	EFFICACY OF AMNION AND PRP FOR TREATMENT OF EXPERIMENTALLY INDUCED WOUNDS IN DISTAL EQUINE LIMBS
MXPA00009733A (en)	2001-11-21	Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses
CN101426460A (zh)	2009-05-06	从角蛋白生物材料形成的涂料和生物医学植入物

Legal Events

Date	Code	Title	Description
2013-04-23	EEER	Examination request	Effective date: 20130404